Compare BY & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BY | ANIP |
|---|---|---|
| Founded | 1914 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2017 | 1999 |
| Metric | BY | ANIP |
|---|---|---|
| Price | $32.51 | $76.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $33.50 | ★ $107.33 |
| AVG Volume (30 Days) | 157.7K | ★ 309.9K |
| Earning Date | 04-22-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | 2.12 | ★ 2.15 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $17.06 | $44.10 |
| Revenue Next Year | $2.84 | $13.18 |
| P/E Ratio | ★ $15.27 | $35.49 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $22.63 | $56.71 |
| 52 Week High | $33.89 | $99.50 |
| Indicator | BY | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 43.96 |
| Support Level | $32.00 | $75.20 |
| Resistance Level | $33.89 | $84.47 |
| Average True Range (ATR) | 0.83 | 2.52 |
| MACD | -0.18 | -0.15 |
| Stochastic Oscillator | 43.46 | 39.91 |
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.